These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9062157)
1. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro. Petru E; Sevin BU; Gottlieb C Gynecol Oncol; 1997 Mar; 64(3):490-2. PubMed ID: 9062157 [TBL] [Abstract][Full Text] [Related]
2. Radiation-induced apoptosis and cell cycle alterations in human carcinoma cell lines with different radiosensitivities. Hunáková L; Chorváth M; Duraj J; Bartosová Z; Sevcíková L; Suliková M; Chovancová J; Sedlák J; Chorváth B; Boljesíková E Neoplasma; 2000; 47(1):25-31. PubMed ID: 10870683 [TBL] [Abstract][Full Text] [Related]
3. Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line. Siler DF; Wheeless CR; Dubin NH Cancer; 1996 May; 77(9):1850-3. PubMed ID: 8646684 [TBL] [Abstract][Full Text] [Related]
4. Comparison of high dose rate, low dose rate, and high dose rate fractionated radiation for optimizing differences in radiosensitivities in vitro. Wilkins RC; Ng CE; Raaphorst GP Radiat Oncol Investig; 1998; 6(5):209-15. PubMed ID: 9822167 [TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
6. Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. De Pooter CM; Scalliet PG; Elst HJ; Huybrechts JJ; Gheuens EE; Van Oosterom AT; Fichtinger-Schepman AM; De Bruijn EA Cancer Res; 1991 Sep; 51(17):4523-7. PubMed ID: 1873796 [TBL] [Abstract][Full Text] [Related]
7. Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines. Gorodetsky R; Mou X; Pfeffer MR; Peretz T; Levy-Agababa F; Vexler AM Isr J Med Sci; 1995; 31(2-3):95-100. PubMed ID: 7744601 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of in vitro radiosensitivity in human bladder cancer cells. Barnetson AR; Banasiak D; Fisher RJ; Mameghan H; Ribeiro JC; Brown K; Brown JL; O'Mara SM; Russell PJ Radiat Oncol Investig; 1999; 7(2):66-76. PubMed ID: 10333247 [TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771 [TBL] [Abstract][Full Text] [Related]
11. Taxol sensitizes human ovarian cancer cells to radiation. Steren A; Sevin BU; Perras J; Angioli R; Nguyen H; Guerra L; Koechli O; Averette HE Gynecol Oncol; 1993 Feb; 48(2):252-8. PubMed ID: 8094062 [TBL] [Abstract][Full Text] [Related]
12. Characterization of highly radiosensitive cell lines from a human ovarian small-cell cancer. Hanson JA; Parry EM; Gibbs AR; Court JB; Pour-Faizi MA; Kerby IJ; Bean EA Gynecol Oncol; 1997 Nov; 67(2):147-53. PubMed ID: 9367698 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822 [TBL] [Abstract][Full Text] [Related]
14. Application of the ATP-cell viability assay for assessment of in vitro radiation treatment response in gynecologic cancer cell lines. Rodriguez M; Steren AJ Contrib Gynecol Obstet; 1994; 19():156-65. PubMed ID: 7995047 [No Abstract] [Full Text] [Related]
15. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide. Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681 [TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227 [TBL] [Abstract][Full Text] [Related]
17. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. Aunoble B; Bernard-Gallon D; Bignon YJ Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099 [TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948 [TBL] [Abstract][Full Text] [Related]
19. Radiosensitivity in multidrug-resistant and cisplatin-resistant human carcinoma cell lines. Gigante M; Toffoli G; Bertola A; Biscontin G; Dassie A; Zanelli GD; Zanin E; Trovò MG; Muzzio PC Am J Clin Oncol; 2003 Aug; 26(4):e73-9. PubMed ID: 12902902 [TBL] [Abstract][Full Text] [Related]
20. Individual radiosensitivity does not correlate with radiation-induced apoptosis in lymphoblastoid cell lines or CD3+ lymphocytes. Wistop A; Keller U; Sprung CN; Grabenbauer GG; Sauer R; Distel LV Strahlenther Onkol; 2005 May; 181(5):326-35. PubMed ID: 15900430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]